 Clovis Oncology Inc NASDAQ: CLVS announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca Rucaparib as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free. 